Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial
Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial
复制标题
DOI：
10.3945/ajcn.114.093906
复制
发表时间：
2015-09-01
影响因子：
7.1
通讯作者：
Weaver, Connie M.
中科院分区：
文献类型：
--
作者：
Pawlowski, Jessica W.;Martin, Berdine R.;Weaver, Connie M.
背景：绝经后雌激素缺乏是骨丢失的一个主要因素。大豆异黄酮对预防绝经后骨质流失有不同的影响，这可能与特定的大豆异黄酮含量或个体的可变雌马酚产生能力有关。目的：我们旨在确定大豆补充剂中大豆异黄酮含量和个体的雌马酚产生能力对绝经后骨钙保留的影响。设计：这项研究是一项盲法、随机、交叉干预试验，在24名绝经后妇女中进行了将大豆苷元转化为雌马酚的能力的预筛选。在干预之前，妇女与Ca-41平衡。干预措施是5种大豆黄酮口服补充剂（2种剂量的富含染料木黄酮的大豆补充剂和3种剂量的不同比例的混合大豆黄酮）和双膦酸盐（利塞膦酸盐）。每种干预措施依次给予50天，然后是50天的洗脱期。骨钙潴留的百分比由尿Ca-41：calcium.Results的变化确定：干预范围从52到220 mg总黄酮/d增加骨钙潴留3.4%和7.6%之间与利塞膦酸钠组的15.3%（95%CI：7.1%，22.7%; P = 0.0014）相比，利塞膦酸钠组为中度疗效（P < 0.05）。最有效的大豆干预提供了105.23毫克总黄酮/天，染料木黄酮，大豆黄酮，黄豆黄素在其自然比例和增加骨钙潴留7.6%（95%CI：4.9%，10.2%; P < 0.0001）。染料木黄酮，52.85毫克/天，增加骨钙潴留3.4%（95% CI：0.5%，6.2%; P = 0.029），但没有好处，在更高的金额（113.52毫克/天）。雌马酚生产者和nonproducers.Conclusion之间的骨钙潴留没有差异（P = 0.5）：大豆异黄酮，虽然不是作为有力的利塞膦酸盐，是有效的骨保存剂在绝经后妇女，无论他们的雌马酚生产状态，和混合异黄酮在其自然比例是更有效的比丰富的染料木素。
Background: Postmenopausal estrogen depletion is a major contributing factor to bone loss. Soy isoflavones have variable effects on the prevention of postmenopausal bone loss, which is possibly related to the specific isoflavone content or the variable equol-producing capacity of individuals.Objective: We aimed to determine the effects of the content of isoflavones in a soy supplement and the equol-producing ability of the individual on postmenopausal bone calcium retention.Design: The study was a blinded, randomized, crossover intervention trial in 24 postmenopausal women who were prescreened for their ability to convert daidzein to equol. Women were equilibrated with Ca-41 before the intervention. Interventions were 5 soy isoflavone oral supplements (2 doses of a genistein-rich soy supplement and 3 doses of mixed isoflavones in various proportions) and a bisphosphonate (risedronate). Each intervention was given sequentially for 50 d followed by a 50-d washout period. The percentage of bone calcium retention was determined from the change in urinary Ca-41: calcium.Results: Interventions that ranged from 52 to 220 mg total isoflavones/d increased bone calcium retention between 3.4% and 7.6% (P < 0.05), which was a moderate effect compared with that of risedronate at 15.3% (95% CI: 7.1%, 22.7%; P = 0.0014). The most-effective soy intervention delivered 105.23 mg total isoflavones/d as genistein, daidzein, and glycitein in their natural ratios and increased bone calcium retention by 7.6% (95% CI: 4.9%, 10.2%; P < 0.0001). Genistein, at 52.85 mg/d, increased bone calcium retention by 3.4% (95% CI: 0.5%, 6.2%; P = 0.029); but there was no benefit at higher amounts (113.52 mg/d). There was no difference (P = 0.5) in bone calcium retention between equol producers and nonproducers.Conclusion: Soy isoflavones, although not as potent as risedronate, are effective bone-preserving agents in postmenopausal women regardless of their equol-producing status, and mixed isoflavones in their natural ratios are more effective than enriched genistein.